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Background: Inflammatory response is one of the key components of pain perception. Continuous infusion (CWI)
of local anesthetics has been shown to be effective in controlling pain and reducing postoperative morphine
consumption, but the effect of adding a potent anti-inflammatory drug (such as a steroid) has never been
addressed. In our study, we want to investigate the effect of CWI with local anesthetic + methylprednisolone on
acute and persistent pain, correlating clinical data with biomarkers of inflammation and genetic background.
Methods/Design: After approval by their institutional review board, three hospitals will enroll 120 patients undergoing
major abdominal surgery in a randomized, double-blind, phase III study. After a 24-h CWI of ropivacaine 0.2 % +
methylprednisolone 1 mg/kg, patients will be randomly assigned to receive either ropivacaine + steroid or placebo for
the next 24 h. Then, patient-controlled CWI with only ropivacaine 0.2 % or placebo (according to the group of
randomization) is planned after 48 h up to 7 days (bolus 10 ml, lock-out 1 h, maximum dose of 40 ml in 4 h). Morphine
equivalent consumption up to 7 days will be analyzed, together with any catheter- or drug-related side effect.
Persistent post-surgical pain (PPSP) incidence will also be investigated. Our primary endpoint is analgesic consumption
in the first 7 days after surgery; we will evaluate, as secondary endpoints, any catheter- or drug-related side effect,
genotype/phenotype correlations between some polymorphisms and postoperative outcome in terms of morphine
consumption, development of the inflammatory response, and incidence of PPSP. Finally, we will collect, in a subgroup
of patients, wound exudate samples by micro-dialysis, blood samples, and urine samples up to 72 h to investigate local
and systemic inflammation and oxidative stress.
Discussion: This is a phase III trial to evaluate the safety and efficacy of wound infusion with steroid and local anesthetic.
The study is aimed also to evaluate how long this infusion has to be maintained in order to maximize effectiveness. Our
data are intended to quantify the amount of ropivacaine and methylprednisolone needed by patients undergoing major
abdominal surgery, to be stored in a new nanotechnology device for sustained pain treatment after surgery. We also aim
to clarify the roles of inflammatory response, oxidative stress, and genetic background on postoperative and persistent
pain after major abdominal surgery.
Trial registration: The trial was registered on ClinicalTrials.gov (NCT02002663) on 24 Oct. 2013.* Correspondence: dariobugada@gmail.com
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Acute postoperative pain is a complex unresolved
phenomenon sustained by various patho-physiological
changes, potentially leading to postoperative morbidity and
persistent post-surgical pain (PPSP) [1], influencing patient
outcome [2–4]. Risk factors for PPSP have not been com-
pletely established yet, but the severity of acute postopera-
tive pain is often mentioned [5]. Therefore, postoperative
pain relief is gaining further interest in the perspective of
an improved long-term outcome after hospital discharge.
Postoperative pain treatment involves different strat-
egies; the paradigm of multimodal analgesia is to combine
different techniques and drugs to improve efficacy and re-
duce side effects. The most challenging target is the
reduction of opioid consumption because, beyond the
well-known respiratory, cognitive, and digestive side ef-
fects, opioids may be associated with immune depression
and distant malignant cell proliferation and expansion
after oncologic surgery [6, 7].
In this perspective, continuous wound infusion (CWI)
has gained increasing interest in the last decade. CWI
prolongs the action of local anesthetics, improving their
efficacy, and has been shown to be effective in control-
ling pain and in reducing postoperative morphine con-
sumption in major surgery [8]. A further advantage of
CWI is the ability to provide a continuous block of pain
stimuli coming from the periphery, thus continuously
providing protection from central sensitization and pain
persistence: the incisional pain model has clearly demon-
strated that single-administration, pre-incision analgesia
(i.e., preemptive analgesia in clinical practice) is of little
interest because when the effects of analgesic treatment
abate, the wound itself is able to restart sensitization
processes. Therefore, the question is how long continu-
ous infusion should be maintained after surgery.
Nevertheless, postoperative pain is due to different
components, and the inflammatory reaction and its non-
resolution are now considered to be important factors
underlying both acute pain and pain persistence after
surgery [1, 9, 10]. A reasonable approach to reduce the
inflammatory response is to modulate its local expres-
sion with anti-inflammatory agents. Despite the studies
that have investigated the efficacy of wound infusion
with non-steroidal anti-inflammatory drugs and despite
proofs of clinical analgesic efficacy [11], it is well known
that cyclooxygenase (COX)-induced enzymes account
only partially for local inflammation and that several
other substances—especially cytokines and interleukins
(ILs)—are involved in the process [12] together with
oxidative stress [13]. Although the relative importance
of each cytokine may differ depending on the type of
surgery, the pro-inflammatory IL-1-β seems to play a
major role in incisional pain: it is required for the induc-
tion and maintenance of incisional pain in animalmodels and may contribute to the variation of postoper-
ative morphine consumption in humans [14]. Thereby,
the modulation of local cytokine production might repre-
sent an attractive alternative for the future developments of
intrawound analgesia [15], and the administration of a
steroid could be more promising than non-steroidal anti-
inflammatory drug infusion [16].
Despite the importance of analgesia, the genetic contribu-
tion is considered a determinant for PPSP development,
and different studies have highlighted the role of genetic
factors on postoperative outcome in terms of analgesic re-
sponse and pain intensity [17, 18].
Literature data demonstrate that the gene codifying
for the adrenergic receptor α-2 (ADRB2), a target for
adrenaline, is characterized by some single-nucleotide
polymorphisms (SNPs) predisposing patients to chronic
pain [19]. Diatchenko et al., genotyping 202 females, found
that particular ADRB2 haplotypes modulate chronic pain
conditions such as temporomandibular disorder [20].
Also, μ opioid receptor-1 (OPRM1) encodes the main re-
ceptor of opioids, and its polymorphisms are correlated to
a significant interindividual difference in the postoperative
consumption of morphine [21–23]. The catecholamine-O-
methyltransferase (COMT) gene (encoding the enzyme that
regulates the levels of catecholamines and enkephalins) has
been associated with the variability of pain sensitivity in ex-
perimental, chronic, and postoperative pain [17, 20, 24].
The UDP-glucuronosyl-transferase 2B7 gene (UGT2B7) is
of particular importance for the metabolism of morphine
[25], but there are still very limited studies of the associ-
ation between polymorphic gene expression, opioid treat-
ment doses, and side effects.
Genetics could also be a predictor of the inflammatory
response. The interleukin-1 receptor antagonist (IL-1Ra)
is the main determinant of the bioactivity of IL-1, and
the corresponding gene is polymorphic: variants of this
gene have recently been demonstrated to be associated
with differences in opioid consumption in the first 24 h
after nephrectomy [26].
In our phase III study, we will investigate the analgesic
effect of CWI with local anesthetic and methylprednisolone
on acute pain and PPSP in the context of open abdominal
surgery. Clinical data will be correlated with biomarkers of
inflammation and to the genetic background in order to in-
vestigate (1) the role of both inflammatory mediators and
oxidative stress in the genesis and maintenance of pain and
(2) the contribution of gene polymorphisms on inter-
individual differences in pain, response to analgesics, and
inflammatory reaction after surgery.
Methods
Design
This is a multicenter, prospective, double-blind, phase III
clinical trial. Three centers are involved in enrollment
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Ospedaliero-Universitaria di Parma, Parma, Italy; and
Humanitas Research Center, Milano, Italy), and two centers
will be in charge of genetic analyses (Azienda Ospedaliero-
Universitaria di Parma) and oxidative stress analyses
(IRCCS San Raffaele Pisana, Rome, Italy).
The present study is part of a wider project approved by
and funded with a grant by the Italian Health Ministry
(“New nanotechnology and biomedical approaches to im-
prove postoperative pain treatment reducing risks related
to opioids” - GR-2010-2318370; Principal Investigator
Massimo Allegri).
This clinical study is locally approved by the institutional
review boards of promoting and participating centers
(Comitato di Bioetica – Fondazione IRCCS Policlinico S.
Matteo; Comitato Etico per Parma – Azienda Ospedaliero-
Universitaria di Parma; and Comitato Etico indipendente –
IRCCS Istituto Clinico Humanitas; reference number PT-
SM-13-YR). The trial is registered on ClinicalTrials.gov
(NCT02002663; Principal Investigator Massimo Allegri).
Patients
Patient eligibility is assessed at the pre-operative
anesthesia consultation. All eligible patients must sign a
specifically designed informed consent form.
Male and females, American Society of Anesthesiologists
I-II-III, from 18 to 85 years old, scheduled to use patient-
controlled analgesia (PCA) with morphine for postoperative
pain control after major abdominal surgery by laparotomy
(gastric surgery, bilious-pancreatic surgery, hepatic resec-
tions, bowel resections, nephrectomy, or any laparotomy
with intra-peritoneal access) are enrolled.
Regular use of opioid analgesics, history of drugs or
alcohol abuse (or both), postoperative hospitalization in
intensive care with sedation or mechanical ventilation
(or both), neurological disorders, any heart conduction
disease, any cognitive or mental disorder hindering a
patient from providing informed consent, body mass
index of more than 30, diabetes (type I or II), allergy to
study drugs, and use of epidural analgesia are exclusion
criteria.
Procedures - clinical study
On the day of surgery, patients come to the operating room
and are provided with standard monitoring (electrocardio-
gram, oxygen saturation, non-invasive blood pressure, and
invasive pressure monitoring). General anesthesia is given
using propofol and midazolam (as deemed appropriate
by the anesthesiologist), opioids (fentanyl 0.2 μg/kg or
remifentanil 0.1-0.25 mg/kg per min or both), and
muscle relaxants (cisatracurium/rocuronium) and main-
tained with sevoflurane.
A morphine bolus of 0.15 mg/kg is given 30 to 45 min
before the end of surgery. An infusion catheter (BaxterPainfusor®; Baxter International, Deerfield, IL, USA) is
placed by the surgeon in the fascial plane between
peritoneum and fascia trasversalis, and a 10-ml bolus of 0.2
% ropivacaine is administered immediately after muscular
plane closure; the catheter is then connected to an
electronic pump (CADD®-Solis; Smiths Medical, Dublin,
OH, USA) to give a continuous infusion of pain
medications.
During the first 24 h, all patients receive ropivacaine 0.2
% + methylprednisolone 1 mg/kg, 10 ml/h (total volume of
240 ml in 24 h) continuous wound infusion; additionally,
either acetaminophen 1000 mg or ketorolac 30 mg every 8
h is prescribed.After 24 h, patients are randomly assigned between two
groups of treatment:
 Treatment group: 10 ml/h continuous infusion of
ropivacaine 0.2 % + methylprednisolone 1 mg/kg
 Placebo group: 10 ml/h continuous infusion of saline
0.9 %.
Regardless of treatment group, rescue analgesia in the
first 48 h is provided by PCA pump with morphine (0.5
mg/ml, bolus 1 mg, lock-out 5 min, 20 mg limit every 4 h).
Random group allocation of patients is made through
a computer-generated sequence. To maintain blinding, a
research fellow who is not taking part in patient evalu-
ation is in charge of preparing and programming all of
the pumps used during the study: an opaque, sealed, se-
quentially numbered envelope is assigned to each patient
and is opened by the same research fellow after the first
24 h of treatment.
Patients and their anesthesiologists are blind to treat-
ment assignment. A clinical resident, who is not in-
volved with randomization, is in charge of all clinical
evaluations as part of the daily clinical practice.
The envelope is maintained apart from the patient’s case
report form and is to be opened in every potentially harm-
ful situation for the patient but only when care providers
need to be aware of the patient’s treatment. All ropivacaine
and methylprednisolone vials used during the study are reg-
istered with their code in order to be tracked and recog-
nized in the future for any issue potentially hindering the
validity of data.
At 48 h, morphine PCA is removed, and all patients are
treated with Patient-Controlled Intrawound Analgesia
(PCA through the wound catheter) with either ropivacaine
0.2 % alone or saline according to the group of
randomization up to a maximum of 7 days after surgery.
The catheter is removed at the seventh postoperative day
or after 36 h of non-use (no self-administered bolus). After
PCA removal, rescue additional analgesia is provided by
Bugada et al. Trials  (2015) 16:357 Page 4 of 8tramadol (100 mg or 50 mg according to patient’s weight of
not more than or of more than 50 kg).
All patients are evaluated at the end of surgery, at 3, 6,
12, 24, 36, and 48 h, and daily to the seventh postoperative
day or until catheter removal by the Acute Pain Service and
twice a day by the surgeons as part of their current clinical
practice. Pain values, analgesic consumption, any drug-
related side effect, and any catheter-related complication
(such as occlusion or dislodgment) are recorded. Patients
are also evaluated by surgeons after discharge, as in the
current practice: any infection or healing retardation is
monitored, together with any pain or sensorial abnormality
to be signaled to the pain practitioners. Regardless, the
Acute Pain Service investigates pain persistence at 1
and 3 months through a phone call, and patients with
PPSP (patients experiencing pain at 1 or 3 months after
surgery) are eventually referred to our pain clinic for
evaluation and treatment.
Procedures - genetic study
We will genotype several SNPs in ADRB2, OPRM1,
COMT, UGT2B7, and IL-1Ra genes in all patients by the
Taqman SNP Genotyping Assays (Applied Biosystems,
Foster City, CA, USA) in the Pain-OMICS core-lab of
Azienda Ospedaliera of Parma.
The peripheral blood samples are collected during gen-
eral anesthesia into EDTA-coated tubes. We extract DNA
by using a QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany) from 200 μl of blood. DNA obtained are stored
at −20 °C for subsequent TaqMan analysis. Amplification is
performed in a volume of 5 μl containing 10 ng of genomic
DNA, SsoFast Probes Supermix (Bio-Rad Laboratories S.r.l,
Segrate, Italy). Cycling and hybridization conditions are set
in accordance with the instructions of the manufacturer.
The amplification and genotyping discrimination are
performed in a LightCycler 480 Real-Time PCR System
(Roche Diagnostics Ltd, Lewes, UK). All assays are used
in accordance with the instructions of the manufacturer
(Life Technologies, Monza, Italy). The SNP calling is
made with LightCycler 480 Endpoint Genotyping software
version 1.5.0.39 (Roche Diagnostics Ltd).
Procedures - inflammatory response study
Inflammatory response will be analyzed on the first 15
patients in each group (for a total of 30 patients). Before
the end of surgery, the surgeon inserts a single-use and
minimally invasive (diameter of 0.5 mm) micro-dialysis
catheter in the fat adjacent to the surgical wound with
sterile technique. The catheter has a cutoff membrane
(length of 30 mm) of 100,000 Da, which allows the mon-
itoring of inflammation in vivo. The catheter’s character-
istics allow extended use without risk of breaking. The
catheter will be connected to a slow-rate infusion pump
with imposition of 3 μl/min of micro-dialysis liquid, ahigh molecular weight (30 g dextran 60/1000 ml) sub-
stance to facilitate the micro-dialysis that remains inside
the catheter. The dialyzed liquid is collected in dedicated
tubes directly in the infusion pump. Sampling will be
performed at 1, 6, 24, 48, and 72 h. Serum samples at
the same time points are collected to compare systemic
and local inflammations. All samples are stored at −80 °C
until analysis. Concentrations of ILs (IL-1, IL-6, IL-8, and
IL-10), interferon-gamma, and tumor necrosis factor-alpha
are analyzed in dialyzed wound samples (local inflamma-
tion) and in serum (systemic inflammation). Cytokine levels
in dialyzed liquid and in serum are tested by enzyme-linked
immunosorbent assay (ELISA) by using a commercial kit.
Procedures - oxidative stress study
Oxidative stress will be analyzed on the first 15 patients
in each group (for a total of 30 patients). Patients are
sampled before surgery, before morphine bolus, and at
24 and 48 h after surgery.
Urine samples are directly aliquoted and stored at
−80 °C; blood samples are collected in EDTA-
containing vials and centrifuged within 30 min at
1000×g for 15 min at 4 °C to obtain the plasma.
Lipid peroxidation is analyzed through the determin-
ation of malondialdehyde with thiobarbituric acid assay
in both plasma and urine. The 8-deoxyguanosine and
poly(ADP-ribose) polymerase (PARP) are determined by
commercial ELISA kits.
Study outcomes
The primary outcome of the study is to investigate whether
a wound infusion of local anesthetic and steroid has a
higher analgesic efficacy compared with placebo during 7
days following surgery, assessed as analgesic consumption:
the primary endpoint will be the reduction of morphine
equivalents required in the first 7 days after surgery.
Secondary outcomes will include the differences in anal-
gesia and side effects within 7 days after surgery. We will
investigate any difference in pain at rest and movement
(i.e., coughing and deep inspiration) by Numeric Rating
Scale (11-point scale from 0 = no pain to 10 = worst
imaginable pain), additional analgesic consumption, side ef-
fects (postoperative nausea and vomiting, sedation, and any
signs of local anesthetic or steroid systemic toxicity), and
incidence of persistent post-surgical pain. Differences in
terms of wound healing or wound infections will be also
assessed up to 3 months to assess any local side effect of
steroid infusion. The degree of inflammatory response/
oxidative stress between groups will be assessed to
analyze the effect of CWI with either treatment or pla-
cebo. We plan to analyze the combined effect of some
polymorphisms (by using a gene-candidate approach) of
genes related to the development of PPSP, pain sensitiv-
ity, opioid response, and inflammatory reaction.
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Sample size calculation was made on the hypothesis that
the average morphine equivalent consumption in patients
receiving local anesthetic and steroids CWI will be reduced
by 50 % as compared with those in the control group. This
assumption comes from (1) our retrospective experience
and audits about analgesic consumption in our institution
and (2) data from previous literature [27]; they both showed
reduction in morphine consumption of 30–50 % in patients
receiving local anesthetic wound infusion. Given this as-
sumption, we need 50 patients per group for a power of 80
% and an α error of 5 %; given an attrition rate of 15–20 %,
120 patients are needed in each group.
We will perform an intention-to-treat analysis, and all
participants will be analyzed once enrolled. We consider
a “dropout” to be any patient not completing the evalu-
ation at 3 months (for any reason).
For descriptive variables, we plan to use mean and
standard deviation for normally distributed variables and
average interquartile range for skewed distributions.
We will perform group comparison by using the
Student’s t test or Mann–Whitney test for quantitative
variables and Pearson’s chi-squared test for categorical
variables. Inflammation, oxidative stress, and genetic
background will be assessed to see whether they are
biological markers that help modulate post-operative
and persistent pain: the difference in inflammatory re-
sponse and oxidative stress will be analyzed by means
in a uni- and multi-variate regression model for re-
peated measures, including time, group, and their
interaction. Variables will be transformed if needed to
satisfy model assumptions. Post-hoc comparisons will
include within-group changes over time and between-
group differences at each assessment. The P value will
be adjusted for multiple tests. Fisher exact test will be
used to evaluate the impact of genetic background.
The odds ratio and 95 % confidence interval will be
computed with logistic regression. The P value to as-
sess statistical significance will be corrected with the
Bonferroni correction depending on the number of
candidate genes tested.
Discussion
Historically, care providers have considered pain a peri-
operative issue able to influence immediate morbidity,
but in the last decade greater attention has been placed
on the long-term effects of unrelieved postoperative
pain, especially PPSP [4, 5]. Postoperative pain is a com-
posed phenomenon, in which different variables have to be
taken into account [28]. Therefore, new multidisciplinary
studies should address pain in a different perspective, head-
ing toward a pathophysiological approach to the different
components of pain perception and not merely to analgesia
expressed as a numeric value in the first days after surgery.Unfortunately, not all of these components are known, and
therapeutic approaches still need to be improved.
When clinicians deal with acute postoperative pain,
the surgical wound is a pivotal target for analgesia;
nociceptors located within the surgical incision are the
origin of pain stimuli coming from the periphery, and
their prolonged activation is one of the causes of cen-
tral sensitization. Inflammation also is a main determin-
ant of pain; a lot of mediators are increasingly expressed
after tissue injury leading to primary hyperalgesia [12], and
IL-1 has been linked to pain persistence [14]; thus, a
therapeutic approach specifically aiming to reduce the
inflammatory response is rational. CWI with non-steroidal
anti-inflammatory drugs seems to provide only partial ad-
vantages [11] (because they act only on COX-associated
mediators, like prostaglandin E), whereas steroids have a
wide anti-inflammatory effect and arguably a great efficacy
against pain perception and chronicization [8, 16]. In our
study, we decided to test the efficacy of CWI with both
local anesthetic and steroids in patients undergoing
major abdominal surgery, configuring the first phase
III clinical trial on continuous deep wound infusion of
methylprednisolone.
Peripheral administration should minimize systemic ad-
verse effects by reducing bioavailability and plasma concen-
tration; otherwise, any data about pharmacokinetics and
potential side effects of continuous infusion of steroids are
available: we therefore decided to exclude patients with any
disease potentially precipitating after steroid systemic ab-
sorption, primarily diabetes (type 1 or 2).
In regard to local side effects, the main concerns are
about wound healing and infections potentially associated
with immune-modulatory action of steroids. Most of the
existing data deal with high doses of systemic steroids
[29, 30]. Up to now, few studies have addressed these
issues in patients receiving peripheral steroids: these
studies are in the orthopedic setting and investigate
only clinical effects of a single-shot administration and
provide no evidence of increased infections or difficult
healing [29, 30]. We therefore plan to clarify the risk/
benefit ratio of continuous administration of methylpred-
nisolone, strictly monitoring wound healing and any poten-
tially harmful effect of CWI.
We decided to treat all the patients with 24-h CWI of
ropivacaine and methylprednisolone. This will enlarge the
sample size for the phase III trial (120 patients) and will
allow us to investigate the differences in locally released cy-
tokines according to suspension of local anti-inflammatory
treatment after the first 24 h. This, in our opinion, does not
configure a methodological bias, as our primary endpoint is
analgesic consumption at 7 days, and we will take care to
evaluate any statistically significant difference in morphine
consumption at 24 h to eliminate any confounding factor
this kind of study design may potentially imply.
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local anesthetics is already documented as a valuable
analgesic strategy [8], switching to a saline infusion after 24
h in the control group may be questioned. Otherwise, pla-
cebo control is still a key feature for high-quality clin-
ical trials in the perspective of determining the actual
effectiveness of treatments. Furthermore, because we are
investigating local inflammation, comparing analgesic
efficacy with cytokine analysis will help clarify whether the
pain-killing effect of CWI is associated either with methyl-
prednisolone’s action or with a “washout” phenomenon
(i.e., on the steroid’s effect on cytokine release rather than
on cytokine dilution by fluid infusion).
We decided to analyze both local and systemic in-
flammatory response for the following reasons. First,
systemic inflammation is advocated to be a risk factor
for postoperative and persistent pain [5], but few data
exist, and failed in the identification of standard values
of inflammatory markers as predictors of pain; there-
fore, we guess our data could configure as a reference
for future studies. Second, we want to investigate
whether local and systemic cytokine expressions are
linked or not, and how. Third, we aim to investigate the
effect of a peripheral block on systemic inflammation be-
cause previous studies have provided an incomplete under-
standing [11]. Furthermore, there is evidence of the role
of free radicals as a crucial mediator of pain of differ-
ent etiologies [31–33], and we will also investigate the
free-radical formation and correlate these data to the
inflammatory response.
The maintenance of CWI up to 7 days could also be
questioned because we traditionally consider the first 48
h after surgery to be the most challenging and to be as-
sociated with the highest pain values, and most of the
studies consider a 2-day infusion after surgery; other-
wise, studies on incisional pain have demonstrated that
sensitization processes tend to restart after suspension
of analgesia [34]. Therefore, an effective nociceptive
block should cover the entire perioperative period, aim-
ing to fight pain until it lasts. Use of patient-controlled
wound infusion arguably allows prolongation of the an-
algesic infusion as deemed necessary by the patient,
without drug overdosing, and will help quantify the aver-
age amount of drugs needed in the first 7 days after
major abdominal surgery. This final issue is to be con-
sidered carefully because our study is part of a wider
one aimed to validate a new nanotech device for pain
treatment: this device is being created by bio-engineers
and will be tested for bio-compatibility in rats. The final
aim is to develop a new analgesic tool to be based on
nanotechnology and to be applied on the surgical wound
in humans for sustained release of pain medications and
growth factors after surgery and to be finally re-
absorbed by tissues. In this perspective, our study is thefirst step of a longer project and is focused on investigating
(1) the efficacy and safety of topical methylprednisolone, (2)
the average dose of pain medications required in the peri-
operative period, and (3) the average needed duration of a
wound infusion.
With this study, we aim to validate the use of methyl-
prednisolone for CWI to reduce morphine consumption
and associated side effects as well as PPSP after abdominal
surgery. Moreover, we want to investigate whether genetic
polymorphisms might be biomarkers for postoperative pain
and opioid consumption. These results should be used to
define delivery times and dosages for the new nanotech-
nology platform we are currently developing for sustained
postoperative pain relief to be used in clinical practice and
should be able to improve perioperative and long-term
outcome for patients.
Trial status
The trial is currently running, all three centers are currently
involved in enrollment, and we have enrolled 46 patients so
far.
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